UK firm Intelligent Fingerprinting has said the highly sensitive fluorescence measurement capabilities of its lateral flow technology could help to accelerate Covid-19 diagnostic testing at the point of care.
The company’s DSR-Plus analysis unit can detect specific drugs or their metabolites in the eccrine sweat collected from fingerprints. Combining this with a dedicated Covid-19 testing cartridges could potentially provide the basis for a test suitable for deployment at a range of locations.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Potential partners interested in this project are encouraged to contact Intelligent Fingerprinting executive chairman Philip Hand.
